Supplementary Figure 1 from Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

Authors :: José Baselga
Alejandro Yovine
Diana Graus Porta
Andrea Kay
Yong Zhang
Michael Shi
Stephanie Deudon
John W. Smith
Hope Rugo
Nicholas Turner
Sara A. Hurvitz
Jose M. Perez-Garcia
Florence Dalenc
Mario Campone
Thomas Bachelot
Fabrice André
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: PDF file - 20K, Dovitinib effectively targets FGFR1 in vivo. FGF23 levels were measured from plasma taken at baseline and during dovitinib treatment in 18, 33, and 20 patients from the FGFR1+/HR+, FGFR1-/HR+, and FGFR1-/HR- patient groups, respectively. Error bars represent the 95% confidence intervals.

Full Text Access

Tools